Indian generic drug major Dr Reddy's Laboratories (BSE: 500124) saw its shares dip 1.2% to 4,411 rupees, as it revealed it has entered into a definitive agreement to acquire the US generic prescription product portfolio of Australia-based Mayne Pharma (ASX: MYX). The latter’s stock was not impacted as the announcement came well after ASX trading had ceased.
The Mayne portfolio includes around 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
For the financial period ended June 30, 2022, Mayne Pharma reported total revenue of $111 million (US$) for the acquired portfolio. Approved high-value products include a hormonal vaginal ring, a birth control pill and a cardiovascular product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze